Sweden’s 30-Year Health Mega-Cohort Opens a Molecular Window on Disease

Sometimes the biggest leaps in medicine come not from a single dramatic discovery but from decades of patient, unglamorous data collection. That is precisely the story behind SIMPLER, the Swedish Infrastructure for Medical Population-based Life-course and Environmental Research, now described in detail in the European Journal of Epidemiology. Built on two of the world’s largest prospective cohorts, SIMPLER has quietly tracked the diets, habits, genes and molecular signatures of more than 100,000 Swedes for over three decades, accumulating more than 2.5 million person-years of follow-up and generating over 1,000 peer-reviewed publications along the way. Its architects argue the resource is now entering a new era, one in which blood, stool, saliva, urine and even fat-tissue biopsies are being interrogated with genomics, proteomics, metabolomics and microbiome sequencing to reveal how everyday exposures translate into disease.

The foundation of SIMPLER is a pairing of cohorts that began humbly. Between 1987 and 1990, all women born between 1914 and 1948 living in two central Swedish counties were invited through a mammography screening programme to answer an 80-item questionnaire about their diet. Seventy-four percent signed on, producing the Swedish Mammography Cohort of 61,433 women. A decade later, in 1997, a nearly identical questionnaire went to men born between 1918 and 1952 in adjacent counties; 49 percent responded, forming the Cohort of Swedish Men with 45,906 participants. Both groups have since completed repeated questionnaires roughly every ten years, with the next major follow-up scheduled for completion in 2028. Crucially, loss to follow-up has been vanishingly small, fewer than half a percent, because Sweden’s national registration system allows researchers to link participants to health registers no matter where they move within the country.

That register linkage is one of the infrastructure’s greatest technical assets. Through participants’ personal identification numbers, SIMPLER connects questionnaire answers to 20 national registers covering clinical diagnoses, causes of death, drug prescriptions and socioeconomic data. The yield of disease events is extraordinary: by the end of 2025, the cohorts had recorded 13,052 incident hip fractures and 18,506 strokes, and 65,264 participants had died. Prescription data reveal patterns that would be impossible to capture by self-report alone, including the finding that nearly 80 percent of participants received at least one antibiotic during follow-up, alongside widespread use of sleep medications and antidepressants. The sheer density of outcomes gives researchers the statistical power to study diseases from cancer and cardiovascular disease to osteoarthritis, endocrine disorders and injuries with unusual precision.

But questionnaires and registers are only half the picture. Nested within the main cohorts sit two comprehensive subcohorts, the Swedish Mammography Cohort Comprehensive subcohorts and the Cohort of Swedish Men Comprehensive subcohort, comprising 8,046 women and 4,773 men. These participants have undergone far deeper probing: detailed health examinations at research clinics in Uppsala and Västerås, including fasting blood sampling, blood pressure measurement, dual-energy X-ray absorptiometry scans of body composition and bone density, grip strength testing, timed walking, cognitive screening and, for the oldest and frailest, examinations conducted in their own homes. Around 1,400 additional variables per participant have been collected in these subcohorts, on top of the more than 4,500 questionnaire- and register-based variables available for everyone.

The biological sampling protocol reflects an unusually complete view of human biology. Blood drawn after an overnight fast is separated into EDTA, lithium-heparin and citrate plasma, serum and buffy coat, all flash-frozen within 45 minutes and stored at minus 80 degrees Celsius, a temperature lowered to minus 70 in 2023 as part of an international effort to shrink biobanks’ carbon footprint. Participants also collect first-morning urine at home, self-collect stool samples up to three days before their clinic visit, and provide saliva for DNA extraction; in one of the more distinctive touches, a small adipose tissue biopsy is taken during the clinic visit, giving researchers a direct readout of long-term fatty acid intake. Around 40,000 saliva samples for DNA were returned by mail in the main cohorts between 2005 and 2009.

Layered on top of this biobank is a multi-omics programme that sets SIMPLER apart. Genome-wide genotyping has been completed or is underway for approximately 51,000 individuals using Illumina screening arrays, and saliva-derived DNA has already contributed to international consortia that identified dozens of new risk loci for breast, ovarian, colorectal and prostate cancer. Proteomic profiling used Olink panels to measure thousands of circulating proteins, first with cardiovascular and metabolism panels and then with the expanded Explore 3072 panel at SciLifeLab. Metabolomics spans untargeted ultra-high-performance liquid chromatography-mass spectrometry, which recovered thousands of metabolite features in both positive and negative ionization modes, and targeted nuclear magnetic resonance assays quantifying 250 metabolites and metabolite ratios. Lipidomics of plasma and adipose tissue and metagenomic sequencing of stool, averaging 51 million reads per sample, round out the molecular portfolio, with roughly 12,800 participants contributing samples for at least one omics analysis.

The scientific payoff has already been substantial. Proteomic studies within the cohorts have linked circulating proteins to body fat mass, incident cardiovascular disease, hip fracture, dietary patterns, meat consumption and physical activity, exposing biological pathways that self-reported data alone could never reveal. Genomic and Mendelian randomization analyses established a causal role for the hormone fibroblast growth factor 21 in improving lipid profiles, reducing alcohol consumption and altering liver function markers. Perhaps most strikingly, metagenomic sequencing of stool samples combined with individual-level antibiotic prescription data has produced one of the largest studies to date connecting antibiotic use with gut microbiome composition, work that also opens a window on antimicrobial resistance in the population.

The infrastructure also excels at untangling the thorny relationship between diet, environment and disease. Validation studies have shown that the food frequency questionnaires perform respectably, with deattenuated correlation coefficients averaging 0.65 for macronutrients against repeated 24-hour recall interviews, and biomarker-based checks, such as the correlation of reported milk intake with pentadecanoic acid in adipose tissue, support their reliability. This rigor has allowed SIMPLER researchers to tackle a genuinely hard problem: the possibility that beneficial effects of foods like fatty fish can be masked by contaminants they carry. Dietary estimates of polychlorinated biphenyls were associated with increased cardiovascular risk, while the fish-derived omega-3 fatty acids themselves were linked to lower risk, a benefit-risk split confirmed with blood biomarkers. Similar approaches have tied cadmium exposure to fractures and shown that residential greenness, drawn from register data, is inversely related to heart attack risk in women.

For the authors, the trajectory points toward ever-greater integration. SIMPLER is slated to merge with the Northern Sweden Health and Disease Study, a 150,000-participant cohort with repeated blood samples for some 65,000 individuals, into a shared platform called SIMPLER 2U, while the WICTORY cohort of 34,000 middle-aged adults in Västmanland is being folded in, with about one-third of its members overlapping the existing cohorts. More ambitiously still, planners hope to extend the resource into a multigenerational cohort by inviting the 174,357 children of participants to provide home-based samples and lifestyle data. Data access runs through a secure, GDPR-compliant workspace on Sweden’s national academic supercomputing infrastructure, open to approved national and international researchers. As chronic disease burdens grow and precision medicine matures, SIMPLER’s blend of deep longitudinal questionnaires, virtually complete outcome capture and genome-to-microbiome molecular data makes it one of the most versatile engines for prevention research anywhere in the world, a quiet Swedish data smorgasbord that is now feeding science on a global scale.

Subject of Research: A Swedish national research infrastructure integrating long-running population cohorts with multi-omics data to study diet, lifestyle, environmental and genetic determinants of health across the life course

Article Title: SIMPLER: the Swedish infrastructure for medical population-based life-course and environmental research

Article References: Warensjö Lemming, E., Carlsson, F., Nguyen, D., Al Jewari, C., Brunius, C., Byberg, L., Engstrand, L., Hyötylainen, T., Håkansson, N., Johansson, I., Kolseth, A.-K., Landberg, R., Larsson, S. C., Leppert, J., Mola-Caminal, M., Olsson, E., Sayols-Baixeras, S., Åkesson, A., Wolk, A., & Michaëlsson, K. (2026). SIMPLER: the Swedish infrastructure for medical population-based life-course and environmental research. European Journal of Epidemiology. https://doi.org/10.1007/s10654-026-01455-6

Image Credits: AI Generated

DOI: 10.1007/s10654-026-01455-6

Keywords: SIMPLER, epidemiology, cohort study, multi-omics, public health, diet, lifestyle, genomics, proteomics, metabolomics, microbiome, register linkage